KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Shares Outstanding (Weighted Average) (2016 - 2026)

Esperion Therapeutics filings provide 9 years of Shares Outstanding (Weighted Average) readings, the most recent being $198.2 million for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 1.65% to $198.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $198.2 million, a 1.65% increase, with the full-year FY2023 number at $103.1 million, up 55.26% from a year prior.
  • Shares Outstanding (Weighted Average) hit $198.2 million in Q3 2025 for Esperion Therapeutics, up from $26.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $198.2 million in Q3 2025 to a low of $26.0 million in Q1 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $65.2 million (2022), compared with a mean of $82.2 million.
  • The widest YoY moves for Shares Outstanding (Weighted Average): up 177.94% in 2024, down 67.81% in 2024.
  • Esperion Therapeutics' Shares Outstanding (Weighted Average) stood at $28.9 million in 2021, then surged by 129.76% to $66.4 million in 2022, then skyrocketed by 55.26% to $103.1 million in 2023, then surged by 89.06% to $194.9 million in 2024, then grew by 1.65% to $198.2 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $198.2 million (Q3 2025), $26.1 million (Q2 2025), and $196.1 million (Q1 2025) per Business Quant data.